Jefferies Downgrades UroGen Pharma to Hold, Lowers Price Target to $10
Jefferies analyst Chris Howerton downgrades UroGen Pharma (NASDAQ:URGN) from Buy to Hold and lowers the price target from $35 to $10.
UroGen Pharma Highlights Results From The First And Largest Post-commercial Utilization Review Of JELMYTO For Pyelocalyceal Solution
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest
UroGen Announces New Data from the OPTIMA II Study; Co Says Data Show Median Durability Of Response Of 24.4 Months For UGN-102, An Investigational Non-Surgical Chemoablative Treatment For Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
-- Results from this ongoing, noninterventional rollover study were presented at the 23rd Annual Society of Urological Oncology (SUO) Meeting in San Diego
Reported Late Thursday, UroGen Announces New Data From The OLYMPUS Trial that Shows Median Durability Of Response Of 28.9 Months For JELMYTO, A Non-Surgical, Chemoablative Treatment For Adults With Low-Grade Upper Tract Urothelial Cancer
--Results from this ongoing, non-interventional, rollover study were presented at the 23rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company
FDA Authorizes An Extension Of The In-Use Period For UroGen Pharma’s JELMYTO Admixture To 96 Hours Following Reconstitution
-- This Extension Increases Flexibility and Efficiency for Customers and Patients --
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers
Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday’s Mid-Day Session
Gainers
Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
79 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.